Cupid, a leading consumer healthcare and FMCG company, has reported that its net profit in the June quarter was up nearly three times to ₹44 crore against ₹15 crore logged in the same period last year, on higher demand across business.Revenue more than doubled to ₹155 crore (₹60 crore) as EBITDA also doubled to ₹60 crore.The company’s international B2B healthcare business continued to witness robust demand across institutional procurement programmes, government tenders and private export markets, providing strong order visibility and a healthy revenue pipeline.Cupid expects sizeable orders across its IVD Kits portfolio from multiple State Governments, along with significant international opportunities following the receipt of CE certifications.Several opportunities are in the final stages of the award process, providing a strong near-term growth pipeline, it said.The company has implemented a minimum 10 per cent price increase across its export portfolio, supporting improved realisations and margin expansion.A favourable forex environment also supported export realisations, while prudent hedging of currency exposure relating to international investments helped mitigate foreign exchange risk, it added.Given the healthy demand, the company has enhanced its FY27 guidance to ₹725 crore-₹750 crore in revenue and ₹210 crore-₹225 crore in net profit.Aditya Kumar Halwasiya, Chairman and Managing Director, Cupid said better execution supported by improving order visibility and sustained demand across core segments have strengthened confidence in the company’s growth trajectory.During the quarter, the business witnessed encouraging momentum on expansion of its presence across modern trade, organised retail and pharmacy channels, he said.The commissioning of the Palava manufacturing facility during Q2 FY27 will further strengthen manufacturing flexibility, enhance supply capabilities and support future growth across both international healthcare and domestic consumer healthcare, and the FMCG businesses, he added.Looking ahead, the company remains focused on disciplined execution, maintaining healthy margins and building a future-ready organisation through continued investments in manufacturing and product innovation, said Halwasiya.Published on August 8, 2026